HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Promising Adjuvant Therapies Emerge in HER2+ Breast Cancer

November 24th 2015

Mohammad Jahanzeb, MD, discusses emerging strategies in the adjuvant treatment of patients with HER2-positive breast cancer.

HER2-Enriched Molecular Subgroup Highly Sensitive to Breast Cancer Regimens

November 24th 2015

The primary analysis of the phase III CALGB 40601 trial found that pathologic complete response to dual HER2 blockade was not statistically higher than anti-HER2 monotherapy. However, there was a high level of intertumoral heterogeneity, and patients with the HER2-enriched subtype had a high pCR with both single and dual anti-HER2 therapy.

Dr. Hudis on Neoadjuvant Treatment of HER2-Positive Breast Cancer

November 23rd 2015

Clifford A. Hudis, MD, FACP, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, takes a deeper look at neoadjuvant treatment for patients with HER2-positive breast cancer.

Long-Term Data Support Neoadjuvant Chemo Regimen in HER2+ Breast Cancer

October 20th 2015

Hans-Christian Kolberg, MD, discusses updated results from a study that showed that neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab demonstrated significant overall survival and disease-free survival activity in patients with HER2-positive early-stage breast cancer.

Blackwell Discusses Emerging HER2-Positive Breast Cancer Agents

October 19th 2015

Kimberly L. Blackwell, MD, discusses the potential for some emerging therapies, as well as the benefits of current treatments for patients with HER2-positive breast cancer.

Multigene Panel May Allow Some HR+/HER2- Breast Cancer Patients to Avoid Chemotherapy

October 13th 2015

Patients with hormone receptor (HR)–positive, HER2-negative breast cancer who have a favorable gene-expression profile may be able to avert chemotherapy and receive endocrine treatment alone.

Adjuvant HER2+ Breast Cancer Care Evolves, But Questions Remain

October 9th 2015

Mohammad Jahanzeb, MD, discusses therapeutic agents that may fit into the adjuvant setting treatment paradigm for HER2-positive breast cancer, the increasing importance of genomic testing, and individualized treatments as multiple agents emerge.

Dr. Chan on ExteNET Trial for HER2+ Breast Cancer

September 27th 2015

Arlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Hope Rugo on Optimizing the Use of Neratinib in HER2+ Breast Cancer

September 21st 2015

Hope Rugo, MD, discusses how to balance the benefits and risks of neratinib, as well as unanswered questions regarding ExteNET, in patients with HER2-positive breast cancer.

Slamon Explores Evolution of HER2-Positive Breast Cancer Treatment

September 21st 2015

Dennis J. Slamon, MD, PhD, discusses the impact of the ADAPT and BOLERO trials and how the increased focus on neoadjuvant therapy with trastuzumab and T-DM1 could transform the treatment of HER2-positive breast cancer.

Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast Cancer

September 14th 2015

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial, which examined T-DM1 in patients with HER2-positive, HR-positive early-stage breast cancer.

Case Study Shows Early Efficacy for Neratinib in HER2-Mutated Metastatic Breast Cancer

September 11th 2015

Treatment with the second-generation HER2/EGFR-targeted TKI neratinib resulted in a partial response and dramatic improvement in functional status for a patient with HER2-mutated breast cancer.

Dr. Kass on Optimal Treatment Sequencing in HER2-Positive Breast Cancer

August 28th 2015

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses challenges associated with optimal treatment sequencing for patients with HER2-positive breast cancer.

Adjuvant Trastuzumab Benefit Elucidated in Small HER2-Positive Breast Cancer

August 28th 2015

Patients with HER2-positive breast cancer that was ≤2 cm experienced a substantial improvement in disease-free and overall survival when treated with adjuvant trastuzumab.

HER2-Positive Breast Cancer Treatment Options Growing

August 25th 2015

Outcomes for patients with HER2-positive metastatic breast cancer are improving as a result of blockade strategies, and more novel agents are in the pipeline.

PIK3CA Confers Resistance to Trastuzumab/Lapatinib Combo in HER2-Positive Breast Cancer

August 14th 2015

Patients with HER2-positive breast cancer who harbor a PIK3CA mutation are less likely to benefit from the combination of trastuzumab plus lapatinib.

Dr. Jahanzeb on Overcoming HER2 Resistance in Breast Cancer

August 4th 2015

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology Oncology, University of Miami's Miller School of Medicine, discusses potential mechanisms for overcoming HER2 resistance in breast cancer.

Dr. Elias on Androgen Receptor Inhibitors in HER2-Positive Breast Cancer

August 4th 2015

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.

Dr. Chagpar on Sequencing Therapies for HER2-Positive Breast Cancer

August 3rd 2015

Anees B. Chagpar, MD, MA, MPH, MBA, FRCS(C), FACS, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses sequencing therapies for patients with HER2-positive breast cancer.

Neoadjuvant Pertuzumab Regimen Approved in Europe for HER2-Positive Early Breast Cancer

July 31st 2015

The European Commission has approved the combination of pertuzumab, trastuzumab, and chemotherapy as a neoadjuvant therapy for adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer who are at high risk of recurrence.

NEXT PAGE
PREVIOUS PAGE